Affiliation: University of Vienna
- Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipientsJ Kletzmayr
Department of Medicine, University of Vienna, Austria
Transplantation 70:1174-80. 2000..Although specific therapy is available with ganciclovir, cytomegalovirus (CMV) disease remains a major problem after renal transplantation especially in CMV seronegative recipients of organs of seropositive donors (D+R-)...
- Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipientsJ Kletzmayr
Department of Medicine, University of Vienna, Vienna, Austria
Transplantation 70:1404-7. 2000..Chronic hepatitis B virus (HBV) infection increases morbidity and mortality in renal transplant recipients (RTR). Lamivudine has shown promising results in patients with chronic hepatitis B, but experience with its use in RTR is limited...
- New developments in the management of cytomegalovirus infection and disease after renal transplantationJ Kletzmayr
Department of Medicine, Division of Nephrology and Dialysis, University of Vienna, Austria
Curr Opin Urol 11:153-8. 2001..The understanding of the effects of cytomegalovirus on long-term graft outcome still needs to be deepened in order to design cytomegalovirus-specific interventions to improve graft survival...
- Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditionsS W Aberle
Institute of Virology, University of Vienna, Kinderspitalgasse 15, A 1095 Vienna, Austria
J Clin Microbiol 39:1972-4. 2001..Results concordant with sequence analysis were obtained with 48 of 56 serum samples from HBV-infected patients undergoing lamivudine therapy. In eight cases, additional minor subpopulations could be identified by the line probe assay...
- C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorptionG A Böhmig
Department of Internal Medicine III, University of Vienna, Vienna, Austria
J Am Soc Nephrol 12:2482-9. 2001..In the majority of patients, IA treatment can restore excellent graft function over a prolonged time period...
- Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter studyG Sunder-Plassmann
Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin III, Vienna, Austria
J Am Soc Nephrol 11:1106-16. 2000..Folic acid at 30 or 60 mg/d but not 15 mg/d results in a rebound of total homocysteine plasma concentrations when treatment is stopped...
- Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells?M C Ignatescu
Division of Nephrology and Dialysis, Department of Medicine III, University of Vienna, Vienna, Austria
Kidney Int Suppl 78:S258-61. 2001....
- Association of two MTHFR polymorphisms with total homocysteine plasma levels in dialysis patientsM Fodinger
Department of Medicine III, Division of Nephrology and Dialysis, University of Vienna, Austria
Am J Kidney Dis 38:77-84. 2001..This study shows that the MTHFR 677TT/1298AA genotype, but not the 677CT/1298AC genotype, is a significant predictor of tHcy plasma levels in dialysis patients...
- Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levelsA Feix
Department of Medicine III, Division of Nephrology and Dialysis, Division of Endocrinology and Metabolism, University of Vienna, Austria
Am J Kidney Dis 38:956-64. 2001..0155; OR, 0.330; 95% CI, 0.126 to 0.861). In summary, our study shows that the 2756A-->G transition of MTR in combination with MTHFR 677TT/1298AA and 677CT/1298AC can be associated with extremely high tHcy plasma levels...